FLORIDA: A new study finds cancer patients who receive chemotherapy – and some targeted treatments – may mount an inadequate immune response to COVID-19 vaccination.
The research has been published inMayo Clinic Proceedings: Journal of Innovation, Quality and Results.
“It is important for cancer patients who are receiving chemotherapy to obtain a COVID-19 vaccine,” said Saranya Chumsri, Mohamed, a Mayo Clinic hematologist and oncologist, and author of the paper.
Dr Chumshree said this advice also applies to cancer patients who are A. are taking cdk 4/6 resistor. These inhibitors are a new class of drugs used to treat hormone-receptor-positive and HER2-negative breast cancers.
Dr. Chumsari said that CDK4/6 inhibitors have not traditionally been considered as immunosuppressive as chemotherapy, but her research on breast cancer patients taking these drugs found they exhibited less optimal neutralizing antibody activity. .
Dr Chumsari recommended that antibody levels be tested in these patients after vaccination, and that they should consider receiving a booster vaccination for COVID-19.
Dr Chumsari anticipates additional data later this year about broad immune responses to COVID-19 vaccination, including cellular and antibody responses in patients receiving chemotherapy and targeted therapy with booster vaccination.
The research has been published inMayo Clinic Proceedings: Journal of Innovation, Quality and Results.
“It is important for cancer patients who are receiving chemotherapy to obtain a COVID-19 vaccine,” said Saranya Chumsri, Mohamed, a Mayo Clinic hematologist and oncologist, and author of the paper.
Dr Chumshree said this advice also applies to cancer patients who are A. are taking cdk 4/6 resistor. These inhibitors are a new class of drugs used to treat hormone-receptor-positive and HER2-negative breast cancers.
Dr. Chumsari said that CDK4/6 inhibitors have not traditionally been considered as immunosuppressive as chemotherapy, but her research on breast cancer patients taking these drugs found they exhibited less optimal neutralizing antibody activity. .
Dr Chumsari recommended that antibody levels be tested in these patients after vaccination, and that they should consider receiving a booster vaccination for COVID-19.
Dr Chumsari anticipates additional data later this year about broad immune responses to COVID-19 vaccination, including cellular and antibody responses in patients receiving chemotherapy and targeted therapy with booster vaccination.
,